Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow VSTM by emailGet an email when VSTM pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about VSTM, unsubscribe in one click. Privacy
📣 What VSTM Says Is Next
1H 2027 · “VS-7375 addresses significant opportunity in multiple KRAS G12D solid tumors with a differentiated profile and compelling anti-tumor activity – Broad clinical development program advancing VS-7375 across multiple tumor types with multiple registration pathways – Three registration-directed Phase 2 trials underway in pancreatic, lung and colorectal cancers, with three Phase 3 trials planned to initiate in 1H 2027”
Company press release, Aug 7, 2026 · SEC filing
by end of 2026 · “At least 1 and no more than 2 prior systemic lines of therapy Primary: ORR by BICR Secondary: DOR Expect to complete enrollment by end of 2026 Part C: Received at least 1 and no more than 3 prior systemic lines of therapy Intracranial ORR by mRECIST v1.1 by BICR FPD in July 2026 32 #No prior TAS-102 (trifluridine and tipiracil) or regorafenib.”
Company press release, Aug 7, 2026 · SEC filing
mid-2027 · “Number of prior therapies (1-3 vs. 4 or more) Inclusion Criteria RAMP 301: International Phase 3 Confirmatory Trial of Avutometinib + Defactinib in Recurrent LGSOC 16 U.S. Secured FDA Accelerated Approval in KRAS-mutated recurrent LGSOC. 2029 2025 RAMP 301: Topline data expected in mid-2027.”
Company press release, Aug 7, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full VSTM picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VSTM and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.